Pharmacological Induction of Fetal Hemoglobin in β-Thalassemia and Sickle Cell Disease: An Updated Perspective
A significant amount of attention has recently been devoted to the mechanisms involved in hemoglobin (Hb) switching, as it has previously been established that the induction of fetal hemoglobin (HbF) production in significant amounts can reduce the severity of the clinical course in diseases such as...
Main Authors: | Rayan Bou-Fakhredin, Lucia De Franceschi, Irene Motta, Maria Domenica Cappellini, Ali T. Taher |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-06-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | https://www.mdpi.com/1424-8247/15/6/753 |
Similar Items
-
Transcriptional regulators of fetal hemoglobin
by: Gabriela Pereira dos Santos, et al.
Published: (2024-11-01) -
The Role of Epigenetics in the Induction of Fetal Hemoglobin: A Combination Therapy Approach
by: Mohammad Ahmadvand, et al.
Published: (2014-03-01) -
Comprehensive analysis of a-and b-thalassemia genotypes and hematologic phenotypes
by: Heng Wang, et al.
Published: (2025-01-01) -
The Long Scientific Journey of Sirolimus (Rapamycin): From the Soil of Easter Island (Rapa Nui) to Applied Research and Clinical Trials on β-Thalassemia and Other Hemoglobinopathies
by: Roberto Gambari, et al.
Published: (2023-09-01) -
Sickle cell disease complications
by: Ersi Voskaridou
Published: (2014-12-01)